- RNA-focused pharmaceutical company Silence Therapeutics said it had reached a settlement and license agreement with Alnylam Pharmaceuticals.

Alnylam would license patents from Silence and pay it a tiered royalty on net sales of Onpattro in the European Union, ranging from 0.33%-to-1.00% through 2023.

All legal proceedings in all jurisdictions between the companies had been resolved under the settlement.

'We are excited for the potential of Onpattro to treat patients with hereditary ATTR amyloidosis polyneuropathy as the first RNAi medicine and are looking forward to following Alnylam's achievements,' chief executive David Horn Solomon said.

Story provided by